Chiesi’s new licensing deal with Haisco; Oxurion to file for bankruptcy; Hong Kong CDMO raises $210M

Chiesi, Hais­co to de­vel­op res­pi­ra­to­ry treat­ment out­side of Chi­na: The com­pa­nies said Mon­day that they plan to work to­geth­er to de­vel­op, man­u­fac­ture and po­ten­tial­ly com­mer­cial­ize a re­versible dipep­tidyl pep­ti­dase 1 in­hibitor out­side of Chi­na, Hong Kong, Macau and Tai­wan. Fi­nan­cial terms of the deal were not dis­closed. Hais­co is cur­rent­ly test­ing the ther­a­py in Phase II stud­ies in Chi­na for bronchiec­ta­sis, a con­di­tion that caus­es a buildup of mu­cus in the lungs.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.